Clinical Trial

RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV

Study acronym: ACHIEV
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase I, randomized, double-blind, placebo-controlled clinical trial to investigate the safety of VRC07-523LS and PGDM1400LS in combination with ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62 prime, MVA.tHIVconsv4 and A244d11gp120/ALFQ vaccination, and the impact on viral load setpoint during analytic treatment interruption (ATI) in people living with human immunodeficiency virus-1 (HIV-1, PLWH) who have initiated or will initiate antiretroviral therapy (ART) during acute HIV-1 infection (AHI).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-06-25; most recent amendment 2025-09-15.
Status change: Active, Not Recruiting → Recruiting 2025-09-15
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-08-01
Trial Details
NCT Number NCT06484335
Lead Sponsor Henry M. Jackson Foundation for the Advancement of Military Medicine
Collaborators: US Military HIV Research Program
Conditions HIV Infections, PLWH, ART, Acute HIV Infection
Enrollment 48 participants
Start Date 2025-03-27
Primary Completion 2027-08-01 (estimated)
Study Completion 2027-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-16